These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35041467)

  • 21. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
    Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC
    J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer activity of bisphosphonates in breast cancer.
    Gnant M
    Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
    Powles T; McCroskey E; Paterson A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates and breast cancer incidence and recurrence.
    Chlebowski RT; Col N
    Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
    Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
    Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
    Kohno N
    Int J Clin Oncol; 2008 Feb; 13(1):18-23. PubMed ID: 18307015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of bone metastases and management of bone health in early breast cancer.
    Gnant M; Hadji P
    Breast Cancer Res; 2010; 12(6):216. PubMed ID: 21172067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant bisphosphonates: a new standard of care?
    Gnant M
    Curr Opin Oncol; 2012 Nov; 24(6):635-42. PubMed ID: 23042123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
    Chukir T; Liu Y; Farooki A
    Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of bisphosphonates in early breast cancer.
    Paterson AH
    Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
    Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
    J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
    Denduluri N; Chavez-MacGregor M; Telli ML; Eisen A; Graff SL; Hassett MJ; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Somerfield MR; Trudeau ME; Wolff AC; Giordano SH
    J Clin Oncol; 2018 Aug; 36(23):2433-2443. PubMed ID: 29787356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy.
    Kohno N; Kokufu I
    Breast Cancer; 2003; 10(1):33-7. PubMed ID: 12525761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
    Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
    J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
    Burstein HJ; Lacchetti C; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Solky AJ; Stearns V; Winer EP; Griggs JJ
    J Clin Oncol; 2016 May; 34(14):1689-701. PubMed ID: 26884586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.